Skip to content

Abstract PR007: Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations

Sep 2026 · Cancer Research · 0 citations

TL;DR

The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive cellular and molecular heterogeneity. How unique malignant states interact with and organize local microenvironments to drive therapy resistance and progression remains poorly understood, limiting tumour profiling and patient stratification. Existing binary transcriptional classifications divide PDAC into classical and basal subtypes, yet many tumors occupy intermediate states within diverse immune and stromal microenvironments. To resolve these states, we performed imaging mass cytometry (IMC) on three serial tissue microarray sections from 218 resected PDACs, targeting epithelial, immune, and stromal compartments, respectively. This generated 2457 multiplexed images profiling >2.6 million cells into 83 cell types. These data were integrated with matched whole-genome sequencing (WGS), single-cell transcriptomics, lesion-level deep spatial proteomics, and clinical outcomes. We identified six reproducible tumour phenotypes spanning the classical-to-basal continuum including classical-like states lacking epithelial differentiation transcription factors, S100A4+ non-basal states, and hybrid intermediate states with distinct clinical associations. Trajectory analyses supported progressive transitions across this continuum and revealed mixtures of epithelial states in most tumours. In parallel, we identified eight recurrent immune and stromal microenvironments with strong tumour-subtype specific associations. To define the molecular programs underlying these spatial states, whole-slide IMC-guided laser capture microdissection mass spectrometry (LCM-MS) of 262 tumour and microenvironment regions identified unique functional programs involving differentiation, ECM organization, metabolic activity, stress response and immune regulation. Matched WGS further revealed genotype-phenotype relationships linking recurrent genomic alterations to specific tumour subtypes and spatial microenvironments. Across patients, both epithelial phenotype and microenvironment composition were associated with overall survival, with poorer outcomes observed along the tumour spectrum. The same epithelial continuum was detected in advanced pancreatic and metastatic liver and lung lesions, supporting its conservation across disease sites. Finally, cross-omic survival modelling showed that combining spatial imaging and genomic features outperformed clinical variables and single-modality models, prioritizing tumour states, fibroblast phenotypes, and copy-number alterations with the greatest prognostic value. Our findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification. Noor Shakfa, Ferris Nowlan, Sibyl Drissler, Tiak Ju Tan, Elizabeth Sunnucks, Edward L.Y. Chen, Cassandra Wong, Brendon Seale, Zhen-Yuan Lin, Michelle Chan-Seng-Yue, Amy Zhang, Sabiq Chaudhary, Chengxin Yu, Michael Geuenich, Golnaz Abazari, Matthew D. Watson, Jiaxi Peng, Somaieh Afiuni-Zadeh, Ayelet Borgida, Ricardo Gonzalez, Sheng-Ben Liang, Klaudia Nowak, Miralem Mrkonjic, Anna Dodd, Julie M. Wilson, Kieran R. Cambell, Jennifer L. Gorman, Robert C. Grant, Jennifer J. Knox, Anne-Claude Gingras, Steven Gallinger, Barbara T. Grünwald, Grainne M. O’Kane, Faiyaz Notta, Hartland W. Jackson. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr PR007.

View source

Similar papers

Sep 2026

Abstract IA002: Spatial microenvironment alterations across the clinical spectrum and genomic landscape of human PDAC

Human pancreatic cancer has a relatively homogenous genome and established classical and basal transcriptional subtypes, but despite this, there exist many intermediate state tumours, and a complex, spatially heterogeneous tumour microenvironment. To identify inter-omic dependencies, we investigated its genotype to p...

Hartland W. Jackson · 0 citations
Sep 2026

Abstract B026: Multimodal spatial profiling uncovers cell state–associated receptor–ligand interactions in pancreatic ductal adenocarcinoma

Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...

Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al. · 0 citations
Review Sep 2026

Abstract PR016: High-plex spatial phenotyping resolves immune organization in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is profoundly immunosuppressive and characteristically exhibits sparse lymphocytic infiltration, yet many tumors harbor focal immune aggregates. The phenotypic diversity and patterns of multicellular organization of these immune aggregates remain incompletely defined. Here, we...

D. Olgun, Dennis Gong, Gabriel Francisco Pozo Mattos Pereira et al. · 0 citations
Review Sep 2026

Abstract B033: Integrating spatial biology and peripheral blood biomarkers to map treatment resistance in pancreatic ductal adenocarcinoma

Despite recent advances in RAS-directed therapy, pancreatic ductal adenocarcinoma (PDAC) remains highly lethal. Surgical resection, chemotherapy, and radiotherapy continue to anchor treatment, but therapeutic resistance is pervasive, and most patients succumb to treatment-refractory residual disease. Advances in sing...

D. Olgun, Beatrice Awasthi, N. Lester et al. · 0 citations
Open access Oct 2026

Spatial Proteomics Uncovers Immune Cell Neighborhoods and Tumor-Immune Interfaces in Pancreatic Ductal Adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with dismal prognosis and limited treatment options. The complex interplay between tumor cells and their microenvironment contributes significantly to treatment resistance, yet technological challenges have hindered comprehensive spatia...

Jason Yeung, Yun-Hao Bai, Hua-Ying Qiu et al. · 0 citations
Open access Oct 2026

Spatial multi-omics uncovers an invasive-desmoplastic cellular community with prognostic and therapeutic implications in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma and profound spatial heterogeneity, yet the multicellular organizational principles governing its tumor microenvironment remain poorly understood. Here, we performed single-cell RNA sequencing (scRNA-seq; n = 9) and spatial transcri...

Chang-Hao Liang, Hua Ye, Hui Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.